SYRE Spyre Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1636282 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-77.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-35.0%
ROA-32.9%
ROIC (approx.)-29.1%
Asset turnover—
Leverage & solvency
Liabilities / assets4.4%
Debt / equity0.00x
Current ratio27.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $886,000 | $2.33M | $18.74M |
| R&D expense | $171.65M | $162.79M | $89.50M | $58.58M | $57.07M |
| SG&A expense | $47.91M | $45.78M | $39.95M | $28.53M | $27.32M |
| Operating income | -$209.56M | -$208.57M | -$242.30M | -$84.78M | -$65.65M |
| Pretax income | -$155.22M | -$207.97M | -$338.82M | -$83.95M | -$65.66M |
| Income tax | -$15,000 | $51,000 | -$26,000 | -$136,000 | $141,000 |
| Net income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | -$65.80M |
| EBITDA | -$209.56M | -$208.57M | -$241.56M | -$83.21M | -$64.07M |
| EPS (basic) | — | — | 13.76 | -24.86 | -25.02 |
| EPS (diluted) | — | — | 13.76 | -24.86 | -25.02 |
| Weighted avg. shares (diluted) | — | — | 6.90M | 3.37M | 2.63M |
| Balance sheet | |||||
| Cash & equivalents | $85.72M | $89.42M | $188.89M | $36.42M | $16.98M |
| Short-term investments | $670.81M | $513.66M | $150.38M | $20.85M | $77.99M |
| Current assets | $777.78M | $608.47M | $341.53M | $62.26M | $98.89M |
| PP&E, net | — | — | $0 | $3.22M | $4.55M |
| Total assets | $777.78M | $608.48M | $341.86M | $71.14M | $109.93M |
| Current liabilities | $58.69M | $54.06M | $31.98M | $14.66M | $20.14M |
| Total liabilities | $62.55M | $90.68M | $73.29M | $20.84M | $25.98M |
| Shareholders' equity | $715.24M | $517.80M | $184.02M | $50.30M | $83.94M |
| Shares outstanding | 78.19M | 60.26M | 36.06M | 2.61M | 49.36M |
| Cash flow statement | |||||
| Operating cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.14M | -$53.72M |
| Capital expenditure | — | $0 | $0 | $38,000 | $573,000 |
| Free cash flow | — | -$157.41M | -$99.91M | -$80.18M | -$54.29M |
| Investing cash flow | -$143.47M | -$353.29M | -$108.39M | $57.01M | -$22.62M |
| Financing cash flow | $309.02M | $410.91M | $361.08M | $42.68M | $1.39M |
| Depreciation & amortization | $0 | $0 | $744,000 | $1.57M | $1.58M |
| Stock-based compensation | $37.61M | $44.83M | $25.68M | $7.11M | $8.04M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.